6785.TWO Alar Pharmaceuticals Inc.
- Market cap
- TWD 4.91B
- P/E
- -
- P/B
- 2.30x
- ROE
- -1.6%
- Dividend yield
- 0.34%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6785.TWO undervalued?
Graham numberThe Graham number of Alar Pharmaceuticals Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alar Pharmaceuticals Inc. fundamental analysis
No fundamental analysis for Alar Pharmaceuticals Inc. yet.
Alar Pharmaceuticals Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmac…
Full company profileAlar Pharmaceuticals Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alar Pharmaceuticals Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 600K | 0.00 | 800K | 469M | 5.82M | 2.75M | 3.00M |
| Gross Profit | 600K | - | 800K | 469M | 3.79M | 2.14M | - |
| Operating Income | -143M | -64.2M | -32.5M | 391M | -67.9M | -168M | -118M |
| EBITDA | -140M | -60.9M | -29.3M | 395M | 41.0M | -74.0M | -25.0M |
| Net Income | -143M | -64.2M | -19.9M | 383M | 18.2M | -79.7M | -39.2M |
| EPS | -2.86 | -1.13 | -0.35 | 6.71 | 0.27 | -1.19 | -0.59 |
| Balance Sheet | |||||||
| Total Assets | 604M | 540M | 523M | 973M | 2.56B | 2.49B | 2.45B |
| Total Liabilities | 5.37M | 5.54M | 8.10M | 76.1M | 64.3M | 84.3M | 72.3M |
| Shareholders' Equity | 599M | 534M | 515M | 897M | 2.49B | 2.40B | 2.38B |
| Cash & Short-term Investments | 584M | 519M | 486M | 896M | 1.41B | 1.79B | 1.80B |
| Total Debt | 1.52M | 949K | 2.69M | 1.41M | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -142M | -63.5M | -32.9M | 404M | -75.3M | -171M | -105M |
| Capital Expenditure | 385K | 1.58M | 1.14M | 6.34M | 1.23M | 2.87M | 0.00 |
| Free Cash Flow | -142M | -65.0M | -34.1M | 397M | -76.5M | -174M | -105M |
| Ratios | |||||||
| ROE | -23.9% | -12.0% | -3.9% | 42.6% | 0.7% | -3.3% | -1.6% |
| ROA | -23.6% | -11.9% | -3.8% | 39.3% | 0.7% | -3.2% | -1.6% |
| Net Profit Margin | -23,799.5% | - | -2,483.9% | 81.5% | 312.4% | -2,894.4% | -1,306.5% |
| Debt to Equity | 0.00x | 0.00x | 0.01x | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alar Pharmaceuticals Inc. dividends
- Dividend yield
- 0.34%
- Forward dividend
- 0.10 TWD
- Payout ratio
- -
- Ex-dividend date
- Aug 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 16.7M | 0.25 | - |
| 2024 | TWD 100M | 1.50 | 551.5% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Alar Pharmaceuticals Inc.
- Insiders 41.04%
- Institutions 10.97%
- Public & others 47.99%
- Shares outstanding 66.8M
- Free float 40.3M
Alar Pharmaceuticals Inc. company profile
- Company name
- Alar Pharmaceuticals Inc.
- Ticker
- 6785.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 32
- Fiscal year end
- December
- Address
- No. 32, Keya Road, Taichung, Taiwan
- Phone
- 886 4 2463 7115
- Website
- alarpharm.com
About Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
Alar Pharmaceuticals Inc. management
2- Dr. Yung-Shun Wen Ph.D.CEO, Manager & Director
- Ms. Vivian KangAccounting Supervisor & Director of Finance